CETO3®: the new Omega

CETO3® is a natural fish oil ingredient which contains a high level of Cetoleic acid (Omega-11) with Omega-3 (EPA and DHA). CETO3® is derived from North Atlantic herring. High levels of Omega-11 is uniquely found in North Atlantic pelagic fish. Omega-11 have proven to increase the human body’s own production of EPA/DHA.

CET03® points of difference

  • Contains Cetoleic acid (Omega-11) and Omega-3 EPA/DHA
  • Cetoleic acid is the main fatty acid in North Atlantic herring
  • Cetoleic acid stimulates and increases the body’s own production of EPA/DHA
  • Single source fish Omega-3 ingredient
  • No fishy smell, taste or unpleasant reflux – can be taken as both liquid and capsule\
  • Immediate processing: from fresh fish to oil takes as little as 30 minutes
  • Human grade production process without any solvent or chemicals
  • Low on pollutants as pelagic fish swim neither up in the surface or bottom of the ocean
  • CETO3® is harvested and produced in Norway
  • Low carbon footprint


Equal effectiveness of omega-3 polyunsaturated fatty acids (n-3 PUFAs) from CET03 and fish oil in elevating the omega-3 index

The nature of the source of omega-3 PUFAs can affect bioavailability of docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA). A new source of omega-3 is CET03® (Omega-11 and Omega-3), unlike Fish oil (FOil), contains high levels of monounsaturated fatty acid Cetoleic acid (Omega-11).

This study aimed to examine the effect of CET03® in healthy subjects on the omega-3 PUFA status over 12 weeks and to compare it with the same length of intervention with fish oil (FOil). The Omega-3 Index, a measurement of the DHA and EPA content of red blood cells compared to the total percentage content of all other identifiable fatty acids, was used to quantify the omega-3 status.


In this randomised double-blind study, 30 participants were randomly allocated to either the:

- CET03® group: DHA+EPA dose: 400 mg/day per 2 capsules, n=14
- FOil group: DHA+EPA dose: 600 mg/day/2 capsules, n=16


Following completion of the 12 week intervention, the increase in Omega-3 Index was comparable between both groups

- CET03®: 5.73 ± 1.38%; p<0.00001
- FOil: 6.24 ± 1.35%; p<0.0003


The results of this study demonstrate that the effect of CET03® on the Omega-3 Index increase over 12 weeks is comparable to FOil. Given that CET03® typically contains 200 mg of EPA/DHA per 1000 mg capsule compared to 300 mg EPA/DHA in the fish oil capsules used in this trial, it would appear from the results of this pilot study, on a pro-rata dose equivalence, that CET03® might deliver a 50% improvement in the Omega-3 Index.


Reference: Wakeman M. Equal effectiveness of omega-3 polyunsaturated fatty acids (n-3 PUFAs) from CET03 and fish oil in elevating the omega-3 index: A 12-week randomized placebo controlled parallel study. International Journal of Scientific Research. 2024;13(1)


For more information, contact Craig Fallshaw at craig@cmgrouponline.com.au

This is presented for informational purposes only. You should not rely on this information as a substitute or replacement for professional medical advice, diagnosis, or treatment. This website includes links to other websites. These links are provided for your convenience only and do not mean that we endorse these sites or the products and services they provide. You acknowledge and agree that we are not responsible or liable for the content or accuracy of these other sites. CMG and its staff do not claim to treat or cure any health conditions mentioned. Always read the label. Follow the directions for use. If symptoms persist, talk to your health professional.

Contact Us

  • 5a/5b Jubilee Avenue, Warriewood, NSW, 2102, Australia
  • 02 9091 0264
  • info@cmgrouponline.com.au
  • www.cmgrouponline.com.au

Request a Quote

Would you like a quote for your new product concept or talk to our sales department?

Contact: Craig Fallshaw

Teams Meeting

Contact Craig for a

Teams Meeting